Table 1.
Baseline characteristics of the RET inhibitor-resistant cohort with RET fusion-positive lung cancer.
| Characteristic | n (%), N = 18 |
|---|---|
| Age at diagnosis, median (range) | 56.5 (30–77) |
| Female | 10 (56) |
| Never or light smoker | 18 (100) |
| Adenocarcinoma | 18 (100) |
| RET fusion | |
| KIF5B-RET | 12 (67) |
| CCDC6-RET | 4 (22) |
| Other | 2 (11) |
| RET inhibitor prior to biopsy | |
| Selpercatinib | 10 (56) |
| Pralsetinib | 7 (39) |
| Pralsetinib, then selpercatinib | 1 (6)* |
| Prior lines of therapy | |
| 0 | 3 (17) |
| 1 | 10 (56) |
| 2 or more | 5 (28) |
| Prior platinum chemotherapy | 13 (72) |
| Prior multikinase inhibitor with anti-RET activity | 4 (22) |
*
One patient underwent a repeat biopsy at resistance to pralsetinib, then started selpercatinib and had another biopsy at resistance to selpercatinib.